Hemab Therapeutics Holdings Inc COAG

$39.29 -0.57 (-1.43%)

Valuation

Market cap
1,836,061,000
Revenue TTM
$0
Net income TTM
$-63,913,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
347,000
Avg volume
530,046
Day's range
$38.77 – $40.19
Shares out
46,731,000
Stochastic %K
47%
Beta
—
Analysts
Strong Buy
Price target
$61.86

Price

Company profile

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 cli...

Show more

Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Phone
(617) 553-3952
Website
https://www.hemab.com
Address
101 Main Street, Suite 1220, Cambridge, United States

Latest news

Stocktwits

Yingtrader7 Nov 13, 9:50 PM
$NSYS ADD $COAG to the list🤑
0 replies
d_risk Nov 10, 9:37 PM
$COAG - Hemab Therapeutics Holdings, Inc. - 10-Q - Updated Risk Factors Hemab says it initiated SOLARA, a pivotal single-arm Phase 3 trial of sutacimig. #riskfactors #secfilings 🟢 Added 🟠 Removed https://d-risk.ai/COAG?filing=PL9tZIYcbeTaHtL5myU-3
0 replies
EarningsInsider Nov 10, 2:02 PM
https://www.marketbeat.com/earnings/reports/2026-11-10-hemab-therapeutics-holdings-inc-stock/ $COAG Hemab Therapeutics Earnings Transcript
0 replies
StocktwitsEarnings Nov 10, 1:45 PM
$COAG Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.58 up 96.78% YoY • As of September 30, 2026, Hemab Therapeutics had $430.2M in cash, cash equivalents, and marketable securities and believes those resources will fund operating expenses and capital expenditure requirements into 2029.
0 replies
GTA_Terminal Nov 9, 3:04 AM
Unusual options activity in $COAG. Both sides are getting paid for here. Somebody expects a move, they just don't agree which way. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=COAG&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=COAG Read the full article for the full details: https://globaltradersacademy.com/articles/hemab-coag-technical-levels-options-flow-mixed-between-37-50-and-49-12?utm_source=stocktwits&utm_medium=social
0 replies
GTA_Terminal Nov 7, 6:29 AM
Dark pool check on $COAG: what traded off the exchanges this session. That came on a day the stock jumped hard, so the question is whether big holders were chasing it or selling into it. Look up any stock's options flow and dark pools on the GTA Terminal, free for 7 days: https://globaltradersacademy.com/start-trial?a=stocktwits&sym=COAG&utm_source=stocktwits&utm_medium=social&utm_campaign=trial&utm_content=COAG Read the full article for the full details: https://globaltradersacademy.com/articles/dark-pool-check-hemab-therapeutics-coag?utm_source=stocktwits&utm_medium=social
0 replies
kshonstocks Oct 29, 3:30 PM
$COAG alert hits its 50 dma b/o
0 replies
Quantumup Oct 15, 3:06 PM
Rodman & Renshaw (a/o 10/12)🏁 $COAG Buy; PT $56 $INCY $NVO Rodman & Renshaw said -- We are initiating coverage of Hemab Therapeutics with a BUY rating and $56 price target based on sutacimig's path to becoming the first approved prophylactic therapy in Glanzmann thrombasthenia, backed by a second engine in Von Willebrand disease. Hemab has spent nearly a decade on coagulation disorders that larger hematology franchises left behind, where decades-old plasma products and short-acting bypassing agents have never given way to a subcutaneous, prophylactic option.
0 replies